Cardiovascular risk factors and recommended lipid goals attainment among patients referred in a tertiary care lipid clinic

European Journal of Internal Medicine

Volumn 22, Issue 4, 2011, Pages 412-417

  Pirro, Matteo ^a   Del Giorno, Rosaria ^a   Lupattelli, Graziana ^a   Mannarino, Massimo Raffaele ^a   Roscini, Anna Rita ^a   Covelli, Domenico ^a   Schillaci, Giuseppe ^a   Pasqualini, Leonella ^a   Bagaglia, Francesco ^a   Siepi, Donatella ^a   Mannarino, Elmo ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Cardiovascular risk factors; Cholesterol; Dyslipidemia; Statin; Target

Indexed keywords

ATORVASTATIN; EZETIMIBE; FLUINDOSTATIN; LIPID; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DYSLIPIDEMIA; FEMALE; GENERAL PRACTITIONER; HIGH RISK PATIENT; HUMAN; LIPID ANALYSIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; PATIENT REFERRAL; SEX RATIO;

CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOLIPIDEMIC AGENTS; INCIDENCE; ITALY; LIPIDS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; RISK FACTORS;

EID: 79960559238     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2011.04.007     Document Type: Article

References (32)

1. J. Stamler, D. Wentworth, and J.D. Neaton Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT) JAMA 256 1986 2823 2828 (Pubitemid 17178359)
2. P.W.F. Wilson, R.B. D'Agostino, D. Levy, A.M. Belanger, H. Silbershatz, and W.B. Kannel Prediction of coronary heart disease using risk factor categories Circulation 97 1998 1837 1847 (Pubitemid 28213628)
3. J.E. Hokanson, and M.A. Austin Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies J Cardiovasc Risk 3 1996 213 219 (Pubitemid 26266496)
4. N. Sarwar, J. Danesh, G. Eiriksdottir, G. Sigurdsson, N. Wareham, and S. Bingham Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies Circulation 115 2007 450 458 (Pubitemid 46184196)
5. B. Lamarche, J.P. Després, S. Moorjani, B. Cantin, G.R. Dagenais, and P.J. Lupien Triglycerides and HDL-cholesterol as risk factors for ischemic heart disease. Results from the Québec cardiovascular study Atherosclerosis 119 1996 235 245
6. P.W. Wilson, R.D. Abbott, and W.P. Castelli High density lipoprotein cholesterol and mortality. The Framingham heart study Arteriosclerosis 8 1988 737 741 (Pubitemid 19005358)
7. B.J. Arsenault, J.S. Rana, E.S. Stroes, J.P. Després, P.K. Shah, and J.J. Kastelein Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women J Am Coll Cardiol 55 2009 35 41
8. J. Stamler, D. Wentworth, and J.D. Neaton Prevalence and prognostic significance of hypercholesterolemia in men with hypertension. Prospective data on the primary screenees of the Multiple Risk Factor Intervention Trial Am J Med 80 1986 33 39 (Pubitemid 16131301)
9. G. Assmann, and H. Schulte The Prospective Cardiovascular Münster (PROCAM) study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease Am Heart J 116 1988 1713 1724 (Pubitemid 19015651)
10. M. von Eynatten, A. Hamann, D. Twardella, P.P. Nawroth, H. Brenner, and D. Rothenbacher Atherogenic dyslipidaemia but not total- and high-molecular weight adiponectin are associated with the prognostic outcome in patients with coronary heart disease Eur Heart J 29 2008 1307 1315 (Pubitemid 351768129)
11. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
12. S.M. Grundy, J.I. Cleeman, C.N. Merz, H.B. Brewer Jr., L.T. Clark, and D.B. Hunninghake Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2004 227 239 (Pubitemid 38924592)
13. C.P. Cannon, B.A. Steinberg, S.A. Murphy, J.L. Mega, and E. Braunwald Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy J Am Coll Cardiol 48 2006 438 445 (Pubitemid 44109954)
14. A. Baessler, M. Fischer, V. Huf, S. Mell, C. Hengstenberg, and B. Mayer Failure to achieve recommended LDL cholesterol levels by suboptimal statin therapy relates to elevated cardiac event rates Int J Cardiol 101 2005 293 298 (Pubitemid 40637627)
15. M. Miller, C.P. Cannon, S.A. Murphy, J. Qin, K.K. Ray, and PROVE IT-TIMI 22 investigators Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial J Am Coll Cardiol 51 2008 724 730 (Pubitemid 351221217)
16. J.J. Kastelein, W.A. van der Steeg, I. Holme, M. Gaffney, N.B. Cater, and P. Barter Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment Circulation 117 2008 3002 3009
17. M.J. Chapman, J.S. Redfern, M.E. McGovern, and P. Giral Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk Pharmacol Ther 126 2010 314 345
18. J.C. Fruchart, F. Sacks, M.P. Hermans, G. Assmann, W.V. Brown, and R. Ceska The residual risk reduction initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia Am J Cardiol 102 2008 1K 34K
19. E.S. Ford, A.H. Mokdad, W.H. Giles, and G.A. Mensah Serum total cholesterol concentrations and awareness, treatment, and control of hypercholesterolemia among US adults: findings from the National Health and Nutrition Examination Survey, 1999 to 2000 Circulation 107 2003 2185 2189 (Pubitemid 36547210)
20. H. Ghandehari, S. Kamal-Bahl, and N.D. Wong Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003-2004 Am Heart J 156 2008 112 119
21. D. Vulic, B.T. Lee, J. Dede, V.A. Lopez, and N.D. Wong Extent of control of cardiovascular risk factors and adherence to recommended therapies in US multiethnic adults with coronary heart disease: from a 2005-2006 national survey Am J Cardiovasc Drugs 10 2010 109 114
22. S. Malik, V. Lopez, R. Chen, W. Wu, and N.D. Wong Undertreatment of cardiovascular risk factors among persons with diabetes in the United States Diabetes Res Clin Pract 77 2007 126 133 (Pubitemid 46590472)
23. J. Genest Jr., and J.S. Cohn Clustering of cardiovascular risk factors: targeting high-risk individuals Am J Cardiol 76 1995 8A 20A
24. T.C. Weng, Y.H. Yang, S.J. Lin, and S.H. Tai A systematic review and meta-analysis on the therapeutic equivalence of statins J Clin Pharm Ther 35 2010 139 151
25. A.C. Sposito, J.A. Ramires, J.W. Jukema, J.C. Molina, P.M. da Silva, and M.M. Ghadanfar Physicians' attitudes and adherence to use of risk scores for primary prevention of cardiovascular disease: cross-sectional survey in three world regions Curr Med Res Opin 25 2009 1171 1178
26. J.D. Neaton, and D. Wentworth Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group Arch Intern Med 152 1992 56 64
27. S.P. Kulkarni, K.P. Alexander, B. Lytle, G. Heiss, and E.D. Peterson Long-term adherence with cardiovascular drug regimens Am Heart J 151 2006 185 191 (Pubitemid 41815352)
28. P.H. Jones, M.H. Davidson, E.A. Stein, H.E. Bays, J.M. McKenney, and E. Miller Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* trial) Am J Cardiol 92 2003 152 160 (Pubitemid 36835963)
29. A.S. Wierzbicki, M.A. Crook, T.M. Reynolds, and G. Jackson Thrombotic vascular events after change of statin Lancet 353 1999 845
30. M.K. Ito, J.C. Lin, A.P. Morreale, D.B. Marcus, R. Shabetai, and T.R. Dresselhaus Effect of pravastatin-to-simvastatin conversion on low-density-lipoprotein cholesterol Am J Health Syst Pharm 58 2001 1734 1739 (Pubitemid 32884865)
31. H. Schuster, P.J. Barter, S. Stender, R.C. Cheung, J. Bonnet, and J.M. Morrell Effects of switching statins on achievement of lipid goals: Measuring effective reductions in cholesterol using rosuvastatin therapy (MERCURY I) study Am Heart J 147 2004 705 713
32. C.M. Ballantyne, M. Bertolami, H.R. Hernandez Garcia, D. Nul, E.A. Stein, and P. Theroux Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II Am Heart J 151 2006 e1 e9